PACLITAXEL AHCL 6 mg/ml
Sponsors
F. Hoffmann-La Roche AG, Centre Regional Lutte Contre Le Cancer, Fondation Franc.Cancerologie Digestive
Conditions
Head and neck squamous cell carcinomaPersistent or Recurrent Rare Epithelial Ovarian Tumorsmetastatic breast cancerstomach cancer stage IV with metastases
Phase 2
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors
Active, not recruitingCTIS2023-508194-89-00
Start: 2021-08-30Target: 57Updated: 2026-01-06
PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer
CompletedCTIS2024-513515-27-00
Start: 2024-07-10End: 2025-09-26Target: 112Updated: 2025-01-20
Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck: CARPACCIO (CARboplatin PAClitaxel Cetuximab IO immuno-oncology)
RecruitingCTIS2024-512297-96-01
Start: 2024-11-26Target: 46Updated: 2026-01-16
A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer
TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study
Not yet recruitingCTIS2024-516576-15-00
Target: 224Updated: 2025-12-02